ProtAffin AG Signs Manufacturing Contract for PA401 with CMC Biologics A/S

GRAZ, Austria----ProtAffin AG, a biotechnology company developing a novel class of biopharmaceutical products that act by targeting cell-surface glycan structures, today announced it has signed a manufacturing contract with CMC Biologics Danish operations, located in Copenhagen, Denmark for manufacture of its lead product PA401 for the treatment of chronic obstructive pulmonary disease .

Vital Signs: New drugs for cystic fibrosis bring hope

Emily Schaller likes to travel as part of the cystic-fibrosis advocacy she does, but the daily regimen she uses to manage her disease weighs her down.

The doctor visit for asthma

Here are key details of the doctor visit for asthma: Ask questions, demonstrate inhaler technique, and draw up an asthma action plan.

Mark Easton

Tension at the heart of UK's drug classification

Riki Ott: The Big Lie: BP, Governments Downplay Public Health Risk From Oil and Dispersants

If oil is so nontoxic, as we're being told, then why are the spill response workers giving hazardous waste training? Our federal government should stop pretending that everything is okay.